In breast cancer, we found prognostic amplifications that were centered around oncogenes, including ERBB2, MYC, and MDM2, while prognostic deletions encompassed tumor suppressors CDKN2A, PTEN, and TP53 (Figure 4G). This evidence concerns the gene CDKN2A and breast cancer.